+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 12Years - 21Years
All Genders
ID06854328

A Study to Confirm Safety and Effectiveness of Prism Device Alongside Usual Care for Adolescents Aged 12 to 21 With Post-Traumatic Stress Disorder PTSD

Led by GrayMatters Health Ltd. · Updated on 2026-05-05

45

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of Prism, a software device used alongside standard care, for treating adolescents aged 12 to 21 with Post-Traumatic Stress Disorder PTSD. Prism uses EEG signals to help patients reduce PTSD symptoms, and this study aims to confirm its safety profile in adolescents, ensuring no serious device-related adverse events occur, similar to prior adult studies. In this open-label, single-arm trial, up to 45 adolescent participants diagnosed with PTSD will receive Prism neurofeedback training. They will complete 15 sessions plus or minus 3 of neurofeedback delivered twice weekly on non-consecutive days over approximately eight weeks. Assessments will take place mid-training after 7 sessions, at the end of treatment after completing the sessions, and one month post-treatment. Participants will undergo clinical evaluations, including safety monitoring and symptom assessments using PTSD scales. Researchers will track safety outcomes one month after treatment, and measure symptom improvements at nine weeks. The study involves regular training sessions, clinical assessments, and follow-up visits, lasting about three months in total from the start of training to final follow-up.

CONDITIONS

Brief Title

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

Research Team

J

Jennifer Yarden

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here